Literature DB >> 22302228

The ARCAD clinical trials program: an update and invitation.

Daniel J Sargent1, Marc Buyse, Alastair Matheson, Richard M Goldberg, Aimery de Gramont.   

Abstract

Mesh：

Year:  2012        PMID： 22302228      PMCID： PMC3286167          DOI： 10.1634/theoncologist.2011-0332

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  9 in total

Review 1.  Biomarkers and surrogate end points--the challenge of statistical validation.

Authors:  Marc Buyse; Daniel J Sargent; Axel Grothey; Alastair Matheson; Aimery de Gramont
Journal:  Nat Rev Clin Oncol       Date:  2010-04-06       Impact factor: 66.675

Review 2.  Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer.

Authors:  Marc Buyse
Journal:  Int J Clin Oncol       Date:  2009-04-24       Impact factor: 3.402

3.  Toward efficient trials in colorectal cancer: the ARCAD Clinical Trials Program.

Authors:  Aimery de Gramont; Daniel G Haller; Daniel J Sargent; Josep Tabernero; Alastair Matheson; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2009-10-19       Impact factor: 44.544

Review 4.  Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis.

Authors:  Xavier Paoletti; Koji Oba; Tomasz Burzykowski; Stefan Michiels; Yasuo Ohashi; Jean-Pierre Pignon; Philippe Rougier; Junichi Sakamoto; Daniel Sargent; Mitsuru Sasako; Eric Van Cutsem; Marc Buyse
Journal:  JAMA       Date:  2010-05-05       Impact factor: 56.272

5.  Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study.

Authors:  Benoist Chibaudel; Franck Bonnetain; Qian Shi; Marc Buyse; Christophe Tournigand; Daniel J Sargent; Carmen J Allegra; Richard M Goldberg; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

Review 6.  Integrating biomarkers in clinical trials.

Authors:  Marc Buyse; Stefan Michiels; Daniel J Sargent; Axel Grothey; Alastair Matheson; Aimery de Gramont
Journal:  Expert Rev Mol Diagn       Date:  2011-03       Impact factor: 5.225

7.  End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

Authors:  Daniel J Sargent; Smitha Patiyil; Greg Yothers; Daniel G Haller; Richard Gray; Jacqueline Benedetti; Marc Buyse; Roberto Labianca; Jean Francois Seitz; Christopher J O'Callaghan; Guido Francini; Axel Grothey; Michael O'Connell; Paul J Catalano; David Kerr; Erin Green; Harry S Wieand; Richard M Goldberg; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2007-09-17       Impact factor: 44.544

8.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

Review 9.  Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials.

Authors:  Marc Buyse
Journal:  Cancer J       Date:  2009 Sep-Oct       Impact factor: 3.360
  9 in total
  4 in total

1.  Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials.

Authors:  Manish R Sharma; Elizabeth Gray; Richard M Goldberg; Daniel J Sargent; Theodore G Karrison
Journal:  J Clin Oncol       Date:  2014-10-27       Impact factor: 44.544

Review 2.  Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology.

Authors:  Richard M Goldberg; Richard Adams; Marc Buyse; Cathy Eng; Axel Grothey; Thierry André; Alberto F Sobrero; Stuart M Lichtman; Al B Benson; Cornelis J A Punt; Tim Maughan; Tomasz Burzykowski; Dirkje Sommeijer; Everardo D Saad; Qian Shi; Elisabeth Coart; Benoist Chibaudel; Miriam Koopman; Hans-Joachim Schmoll; Takayuki Yoshino; Julien Taieb; Niall C Tebbutt; John Zalcberg; Josep Tabernero; Eric Van Cutsem; Alastair Matheson; Aimery de Gramont
Journal:  J Natl Cancer Inst       Date:  2022-06-13       Impact factor: 11.816

3.  Toward a Tiered Model to Share Clinical Trial Data and Samples in Precision Oncology.

Authors:  Stefanie Broes; Denis Lacombe; Michiel Verlinden; Isabelle Huys
Journal:  Front Med (Lausanne)       Date:  2018-01-29

4.  The Evolution of Clinical Trials in Oncology: Defining Who Benefits from New Drugs Using Innovative Study Designs.

Authors:  Richard M Goldberg; Lai Wei; Soledad Fernandez
Journal:  Oncologist       Date:  2017-06-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.